FIELD: chemistry.
SUBSTANCE: disclosed are anti-5T4 antibodies, nucleic acids which encode variable regions of such antibodies, antibody/drug conjugates, a method of delivering a drug using such a conjugate, as well as a method of treating a subject with cancer which is characterised by 5T4 antibody expression, by administering the disclosed conjugate.
EFFECT: present invention can further be used in therapy of 5T4-associated diseases.
42 cl, 8 ex, 15 tbl, 15 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| "ANTIBODY-DRUG" CONJUGATES | 2012 |
|
RU2624141C2 |
| ANTI-PTK7 ANTIBODY-DRUG CONJUGATES | 2015 |
|
RU2708075C2 |
| HUMANIZED ANTI-VEGF MONOCLONAL ANTIBODY | 2020 |
|
RU2809746C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND ITS ANTIBODY-DRUG CONJUGATE | 2022 |
|
RU2814164C2 |
| ANTIGEN-BINDING CONSTRUCTS AGAINST TARGET MOLECULES | 2016 |
|
RU2765242C2 |
| HUMANISED ANTI c-met ANTAGONISTS | 2005 |
|
RU2398777C2 |
| HUMANISED ANTI-BETA 7 ANTAGONISTIC ANTIBODIES AND USE THEREOF | 2005 |
|
RU2453558C2 |
| HUMANISED ANTIBODIES AGAINST CD79b AND IMMUNOCONJUGATES AND METHODS OF APPLICATION | 2008 |
|
RU2557319C2 |
| ANTIBODIES AND IMMUNOCONJUGATES RENDERED BY IMMUNO-POSITRON EMISSION TOMOGRAPHY, METHODS OF APPLICATION | 2011 |
|
RU2613886C2 |
| Fab FRAGMENT OF HUMANIZED ANTIBODY AGAINST VEGF AND ITS USE | 2020 |
|
RU2802960C2 |
